OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Alibaba Shares Fall as AI Spending Hits Profit 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Add as a preferred source on Google
EMERYVILLE, Calif., May 04, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 9, 2018, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, May 9th @ 4:30pm Eastern Time/1:30pm Pacific Time
| Toll Free: | 866-548-4713 |
| International: | 323-794-2093 |
| Conference ID: | 7186111 |
| Webcast: | http://public.viavid.com/index.php?id=129538 |
| Replays, available through May 23rd | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 7186111 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
